Douglas H. Thamm

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Lee Honigberg, Ashley M. Smith, Mint Sirisawad et al. · Proceedings of the National Academy of Sciences · 2010 · 1.5K citations · Full text

Immunology, Pathology, Immunologic Mechanism +16

Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (<scp>VCOG</scp>) consensus document

Sandra Nguyen, Douglas H. Thamm, David M. Vail et al. · Veterinary and Comparative Oncology · 2013 · 417 citations

Veterinary Medical Oncology, Consensus Document, Medicine +14

Polymer-Modified Gadolinium Metal-Organic Framework Nanoparticles Used as Multifunctional Nanomedicines for the Targeted Imaging and Treatment of Cancer

Misty D. Rowe, Douglas H. Thamm, Susan L. Kraft et al. · Biomacromolecules · 2009 · 279 citations

Autophagy and Cancer Therapy

Andrew Thorburn, Douglas H. Thamm, Daniel L. Gustafson · Molecular Pharmacology · 2014 · 278 citations · Full text

Evaluation of a 6-Month Chemotherapy Protocol with No Maintenance Therapy for Dogs with Lymphoma

Laura D. Garrett, Douglas H. Thamm, Ruthanne Chun et al. · Journal of Veterinary Internal Medicine · 2002 · 268 citations